Clinical

Dataset Information

0

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer


ABSTRACT: PD1 antibody is now recommended for dMMR/MSI-H metastatic colorectal cancer patients as second line. Chemoradiotherapy is standand treatment for locally advanced rectal cancer and is also recommended as an alternative choice for unresectable locally advanced colon cancer. Thus, this study will investigate the efficacy and toxicity of combination strategy using PD1 antibody and chemoradiotherapy for dMMR/MSI-H locally advnaced colorectal cancer patients.

DISEASE(S): Dmmr Colorectal Cancer,Locally Advanced Colorectal Cancer,Colorectal Neoplasms,Msi-h Colorectal Cancer

PROVIDER: 2332565 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2332769 | ecrin-mdr-crc
2021-06-04 | GSE145037 | GEO
2015-08-01 | E-GEOD-65208 | biostudies-arrayexpress
2023-06-01 | GSE211221 | GEO
2023-06-01 | GSE210018 | GEO
2021-04-07 | GSE149206 | GEO
2023-07-29 | GSE201871 | GEO
| 90202 | ecrin-mdr-crc
| 2717352 | ecrin-mdr-crc
2024-04-19 | PXD044028 | Pride